Immunodermatology News

Despite their much-touted potential to drastically lower the cost of pricey biologics and improve care for patients across a spectrum of diseases, biosimilars have been slow to take root across the country, particularly in comparison with Europe.

The situation with COVID-19, or the currently circulating coronavirus, is developing so rapidly that new information may likely be available by the time you reach the end of this paragraph. But along with factual information, misinformation also abounds on social media, on cable news channels and in print publications. Healio Rheumatology will attempt to set the record straight for health care providers looking to sort out fact from fiction.

Paraproteinemia and malignancies such as multiple myeloma are the two primary diagnostic criteria proposed for necrobiotic xanthogranuloma, according to a recent report.

Rituximab may be a promising option for treatment-refractory childhood-onset lupus erythematosus panniculitis, according to a retrospective, observational case series published in JAMA Dermatology.

MIAMI BEACH, Fla. — Here at the South Beach Symposium, meeting chair Mark S. Nestor, MD, PhD, reviewed current and future treatment options for psoriasis.

There is an increased risk for developing inflammatory arthritis among patients with hidradenitis suppurativa, according to a population-based cohort study published in JAMA Dermatology.

Some 500 dermatologists will gather in Maui at the end of January for the sixth annual Maui Derm for Dermatologists meeting. If all goes as planned, they will leave the Hawaiian island with actionable strategies to put to immediate use in the clinic.

Oral lichen planus is more likely to occur in non-Asian countries and among women, according to results of a meta-analysis investigating this disease.

A multimodal approach that includes not only topical and systemic therapies but also laser and light-based therapies is recommended for hidradenitis suppurativa, according to a recent review article.

The investigational IL-17A and IL-17F inhibitor bimekizumab was superior to adalimumab in achieving a 90% improvement in Psoriasis Area and Severity Index score after 16 weeks, according to a press release from UCB.